266 filings
Page 2 of 14
CORRESP
j32kofgr rkdt99z
6 Oct 23
Correspondence with SEC
12:00am
CORRESP
tz3mbt5t4w4h7 ptpagz
3 Oct 23
Correspondence with SEC
12:00am
UPLOAD
w3inov
26 Sep 23
Letter from SEC
12:00am
8-K
olz954
18 Sep 23
Updated Phase 1 results selected for a poster presentation at ESMO 2023
7:05am
8-K
158e6r
15 Sep 23
Amendments to Articles of Incorporation or Bylaws
7:56pm
8-K
93rtig
8 Aug 23
ESSA Pharma Provides Corporate Update and Reports Financial Results for Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients ongoing
7:15am
8-K
rztx0zj
6 Jun 23
ESSA Pharma Appoints Lauren Merendino to its Board of Directors
4:15pm
8-K
azqptj
9 May 23
ESSA Pharma Provides Corporate Update and Reports Financial Results for Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients ongoing
9:01am
8-K
6b2140b ui7
12 Apr 23
ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer
7:02am
8-K
r7k481d21te0fn2tea2q
10 Mar 23
Submission of Matters to a Vote of Security Holders
12:50pm
8-K
vmqkihfr
7 Feb 23
Completion of Phase 1 EPI-7386 combination study with enzalutamide expected in 1H2023 followed by initiation of the randomized Phase 2 study
7:02am
8-K
f8hpnf9wqbjsrg67au
13 Dec 22
ESSA Pharma Provides Corporate Update and Reports Financial Results for Clinical and Corporate Highlights for 2022 Fiscal Year
7:01am
8-K
6bodrq
31 Oct 22
ESSA Provides an Update on its Clinical Collaboration with Janssen
7:11am